There are two very good possibilities.
1. As Oppenheimer is hired to figure out strategic alternatives, and management has great track records and contacts in bio-pharma industry, I bet a buyout. Atleast $2B price tag. That's somewhere near $100/sh(around 20M o/s). Bidding war very possible and that can increase price tag. Also a strong partnership with big pharma possible, for example let's say SPHS could get upfront $100M milestone payment to finish the rest of the thing needed to bring PRX-302 BPH indication in the market. World's first biotech company Genentech (a giant today) had hardship for cash after few years of its startup. Roche then invested big in Genentech and later it bought Genentech at $48B price tag. However Roche got Genetech way lot cheaper because it was early investor. Similar situation for SPHS could possible with Merck, Pfizer or GSK on board.
OR
2. Data is heavily strong. PRX-302 for BPH is near commercialization as it successfully complete one Phase-3 with strong efficacy and safety. Phase-2 is for PC indication, and that data is also super strong. The drug's mechanism of action is very unique and robust. so it wont be that difficult to find big investors to raise cash. If they issue 10M new shares at $10/sh at this stage, they will have $100M cash and practically no dilution. That cash will be used to finish second phase-3 for BPH indication, filing NDA and getting approval. This path could make SPHS really very big in next 5 years.
So either way, it's a great investment with low rick. I guess after doing DD over past several weeks, big boys now loading. What could be the stock price before any deal is announced? I am hoping $10+ next week.
News 
Market Data 
Discover 
